The first NHS Trust of the PathLAKE Plus consortium has signed an individual contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics. Aiforia Technologies Plc previously announced in February a contract award allowing 25 NHS Trusts of the PathLAKE Plus consortium to purchase Aiforia artificial intelligence solutions in the UK. This contract award enables Trusts to purchase Aiforia solutions directly and to sign individual contracts without a separate tender process.

The CE-IVD marked Aiforia Clinical AI Model for Lung Cancer; PD-L1 is intended for use by pathologists in supporting them with the detection and calculation of PD-L1 biomarker levels in non-small cell lung cancer cases. The clinical grade deep learning artificial intelligence model can automatically detect tumor areas in a patient sample and calculate PD-L1 negative and positive cells.